236 related articles for article (PubMed ID: 25585100)
1. Pancreatic cancer, treatment options, and GI-4000.
Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer, treatment options, and GI-4000.
Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
Hum Vaccin Immunother; 2015; 11(4):931-7. PubMed ID: 25933185
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
4. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
5. [Probability of vaccine therapy for pancreas cancer].
Takahashi M; Togou S; Yamaoka H; Ichikawa H; Shimada H; Cheever MA
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1676-8. PubMed ID: 8886043
[TBL] [Abstract][Full Text] [Related]
6. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.
Suso EM; Dueland S; Rasmussen AM; Vetrhus T; Aamdal S; Kvalheim G; Gaudernack G
Cancer Immunol Immunother; 2011 Jun; 60(6):809-18. PubMed ID: 21365467
[TBL] [Abstract][Full Text] [Related]
7. Mutated Ras peptides as vaccines in immunotherapy of cancer.
Gjertsen MK; Gaudernack G
Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
9. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
[TBL] [Abstract][Full Text] [Related]
10. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
Garrido-Laguna I; Hidalgo M
Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
[TBL] [Abstract][Full Text] [Related]
12. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer).
Yoshimura K; Olino K; Edil BH; Schulick RD; Oka M
Surg Today; 2010 May; 40(5):404-10. PubMed ID: 20425541
[TBL] [Abstract][Full Text] [Related]
13. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
14. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
16. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
17. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
[TBL] [Abstract][Full Text] [Related]
18. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.
Gjertsen MK; Bakka A; Breivik J; Saeterdal I; Solheim BG; Søreide O; Thorsby E; Gaudernack G
Lancet; 1995 Nov; 346(8987):1399-400. PubMed ID: 7475823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
